Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190612 | 0.90 | GPR119 (0.44) | CHEK2TBK1SYK | |
| SCHEMBL20281697 | 0.83 | CHEK2 (0.51) | CHEK2P2RX3P2RX2PIK3CD | |
| SCHEMBL2658979 | 0.83 | TRPV4 (0.40) | GRM5MAP3K12SMN1; SMN2SYK | |
| SCHEMBL21999105 | 0.80 | CHEK2 (0.53) | CHEK2P2RX3P2RX2PIK3CD | |
| SCHEMBL191004 | 0.80 | GRM5 (0.43) | GRM5SMN1; SMN2SYK | |
| SCHEMBL190625 | 0.79 | GRM5 (0.51) | GRM5SYK | |
| SCHEMBL190408 | 0.79 | CHEK2 (0.51) | CHEK2P2RX3P2RX2PIK3CD | |
| SCHEMBL23791463 | 0.77 | PIK3CD (0.51) | PIK3CD | |
| SCHEMBL20281604 | 0.77 | CHEK2 (0.55) | CHEK2P2RX3P2RX2PIK3CD | |
| SCHEMBL21604523 | 0.77 | CHEK2 (0.55) | CHEK2P2RX3P2RX2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1986645-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | CHEK2 1337/4885P2RX3 4302/4885P2RX2 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.